Ted Tisch, Janice Chen, Lucas Harrington, Trevor Martin and Peter Nell. (Mammoth)

January 30, 2020 12:21 PM ESTUpdated January 30, 08:48 PM

Doudna-founded CRISPR upstart bags $45M for new Cas research, extends its reach into therapeutics

Amber Tong

The South San Francisco-based CRISPR upstart that set out to develop diagnostics under co-founder Jennifer Doudna’s guidance is back with $45 million in funding …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Doudna-founded CRISPR upstart bags $45M for new Cas research, extends its reach into therapeutics

Amber Tong

Sign up to read this article for free.

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Acadia snaps up an essential tremor drug after field's summer setbacks

The Biden administration wants Medicare and Medicaid to cover GLP-1s. Will the Trump White House allow it?

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Doud­na-found­ed CRISPR up­start bags $45M for new Cas re­search, ex­tends its reach in­to ther­a­peu­tics

Amber Tong

Sign up to read this article for free.

more like this

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Aca­dia snaps up an es­sen­tial tremor drug af­ter field­'s sum­mer set­backs

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Doudna-founded CRISPR upstart bags $45M for new Cas research, extends its reach into therapeutics

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Acadia snaps up an essential tremor drug after field's summer setbacks

The Biden administration wants Medicare and Medicaid to cover GLP-1s. Will the Trump White House allow it?

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks